Azoximer
Azoximer bromide, sold by the trade name Polyoxidonium by Petrovax NPO, is a water-soluble cationic polymer, adjuvant for use with the hemagglutinin glycoprotein-based influenza vaccine Grippol. Azoximer bromide is a ternary copolymer of 1,4-ethylene piperazine, 1,4-ethylene piperazine-N-oxide, and (N-carboxymethylene)-1,4-ethylene piperazinium bromide with a molecular weight of 60–100 kDa. A derivative of poly(1,4-ethylene piperazine), it is synthesized by a partial oxidation of the parent polymer with hydrogen peroxide to introduce N-oxide groups followed by the quaternization of non-oxidized amino groups with bromoacetic acid. — Wikipedia
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 2012 (NCT02787863)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Immunomodulator
Also displays antitoxic, detoxifying and antioxidant properties.
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAzoximer bromide ↗
- ChEMBLCHEMBL4650378 ↗
Also known as
- polioxidonium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04381377 | Phase 2/Phase 3 (Phase 3) | Apr 29, 2020 | NPO Petrovax Pharm LLC, University of Montpellier |
| NCT03840135 | Phase 3 | Nov 7, 2018 | NPO Petrovax Pharm LLC |
| NCT02787863 | Phase 4 | Sep 1, 2012 | Institute of Sera and Vaccines RAS, Moscow, Pfizer, Russian Academy of Medical Sciences |
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NPO Petrovax Pharm LLC | For profit | 2 | 2 | 1 | 2018 |
| Institute of Sera and Vaccines RAS, Moscow | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Pfizer | For profit | 1 | 0 | 1 | 2012 |
| Russian Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Montpellier | Academic/Hospital | 1 | 0 | 1 | 2020 |